Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Study to Evaluate the Safety and Efficacy of Adding Daclatasvir to the Combination of Sofosbuvir (SOF) and Ribavirin (RBV) for 16 Weeks Versus 24 Weeks in Cirrhotic Subjects With Chronic Hepatitis C Infection Genotype 3

NCT02304159 is registered in ClinicalTrials.gov with Tarek I. Hassanein, M.D., FACP, FAG, AGAF as lead sponsor.

NCT NCT02304159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02304159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Study to Evaluate the Safety and Efficacy of Adding Daclatasvir to the Combination of Sofosbuvir (SOF) and Ribavirin (RBV) for 16 Weeks Versus 24 Weeks in Cirrhotic Subjects With Chronic Hepatitis C Infection Genotype 3
Lead sponsor
Tarek I. Hassanein, M.D., FACP, FAG, AGAF
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2015
Completion date
August 31, 2017
Enrollment
39 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, hepatitis c